Board Member
Five Point Holdings, LLC (FPH)Equibles does not estimate personal net worth.
Get an email with a short summary when Moleculin Biotech, Inc. publishes a filing, an earnings call transcript or a press release.
Get MBRX alertsJonathan Foster is recorded as CFO at Moleculin Biotech, Inc. (MBRX) and Board Member at Five Point Holdings, LLC (FPH) since January 1, 2016. The newest filing on record that lists Jonathan Foster as CFO at Moleculin Biotech, Inc. (MBRX) is dated August 24, 2026. The newest filing on record that lists Jonathan Foster as Board Member at Five Point Holdings, LLC (FPH) is dated April 24, 2026. The proxy statement of Moleculin Biotech, Inc. reports total compensation of $907,268 for Jonathan Foster in fiscal 2025, including a base salary of $405,000. Disclosed compensation is on record for 8 fiscal years. Jonathan Foster has spoken on 9 earnings calls across 1 company, most recently for Moleculin Biotech, Inc. on May 14, 2025. Moleculin Biotech, Inc. is classified in the Biotechnology industry within the Healthcare sector. Five Point Holdings, LLC is classified in the Real Estate - Development industry within the Real Estate sector. Other leadership on record at Moleculin Biotech, Inc. includes Walter Klemp (CEO), Walter V. Klemp (CEO and Board Member), Elizabeth A. Cermak (Board Member) and 4 others.
“We ended the quarter with about $8 million cash on hand. This should run our operations into the third quarter of this year. To get us well into the first quarter of 2026, we will need to raise approximately $15 million.”
“We concluded the quarter with $9.4 million in cash. This is sufficient to carry us into the first quarter of 2025, accounting for our fully diluted shares outstanding, which also includes the pre-funded warrants.”
“For the quarter, R&D expense was $4.3 million versus $5.7 million in the same period a year ago. The decrease of $1.4 million is mainly related to the clinical trial activity decreasing as we're winding down MB-106 and MB-107 trials compared to a year ago.”
“We ended the year with roughly $24 million in cash on hand, sufficient to take us into the fourth quarter of this year.”
“We ended the quarter with roughly $25 million in cash on hand, and our balance sheet remained clean with no debt and little overhang with warrants.”
2016-01-01–present
Last confirmed April 24, 2026
Start not stated–present
Last confirmed August 24, 2026
Biotechnology · Healthcare
CFO
Real Estate - Development · Real Estate
Board Member
2016-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Moleculin Biotech, Inc. (MBRX) | Executive Vice President and Chief Financial Officer | $405,000 | $907,268 |
| 2024 | Moleculin Biotech, Inc. (MBRX) | Executive Vice President and Chief Financial Officer | $405,000 | $989,639 |
| 2023 | Moleculin Biotech, Inc. (MBRX) | Executive Vice President and Chief Financial Officer | $405,000 | $840,642 |
| 2022 | Moleculin Biotech, Inc. (MBRX) | Executive Vice President and Chief Financial Officer | $405,000 | $1,092,252 |
| 2021 | Moleculin Biotech, Inc. (MBRX) | Executive Vice President and Chief Financial Officer | $392,500 | $1,149,177 |
| 2020 | Moleculin Biotech, Inc. (MBRX) | Executive Vice President and Chief Financial Officer | $375,000 | $946,594 |
| 2019 | Moleculin Biotech, Inc. (MBRX) | Executive Vice President and Chief Financial Officer | $360,417 | $838,941 |
| 2018 | Moleculin Biotech, Inc. (MBRX) | Executive Vice President and Chief Financial Officer | $323,333 | $845,689 |
